Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | DY3K7 | — |
16 month-old patient received Boostrix; Dtap vaccine as the 4th dose in the Dtap series; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 16-month-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number DY3K7, expiry date 14-JUN-2027) for prophylaxis. On 04-APR-2025, the patient received Boostrix. On 04-APR-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 16 month-old patient received Boostrix) and inappropriate schedule of vaccine administered (Verbatim: Dtap vaccine as the 4th dose in the Dtap series). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-APR-2025 Nurse reported that a 16 month old patient received Boostrix instead of Dtap vaccine as the 4th dose in the Dtap series, which led to inappropriate age at vaccine administration and inappropriate schedule of vaccine administered. The nurse asked for recommendations on this topic.